Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th
Oakville, Ontario--(Newsfile Corp. - September 5, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in producing the purest pharmaceutical CBD products and developing innovative therapies for heart disease, today announced that David Elsley, President & Chief Executive Officer, will present live at the KCSA Cannabis Investor Conference at VirtualInvestorConferences.com on Thursday, September 12th. Date: Thursday, September 12th Time: 12:00 -...
2019-09-05 3:36 PM EDT
Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
Oakville, Ontario--(Newsfile Corp. - July 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), focused on producing pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure, announces today that David Elsley, President and CEO of Cardiol, will be presenting at the Canaccord Genuity 39th Annual Growth Conference being held August 7-8, 2019 at the InterContinental...
2019-07-25 9:53 AM EDT
Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation
Oakville, Ontario--(Newsfile Corp. - June 20, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its CardiolRx CBD formulation. CardiolRx is Cardiol's pure pharmaceutically-produced CBD. Designed to be the safest...
2019-06-20 9:06 AM EDT
Cardiol Therapeutics Reports Results of its AGM
Oakville, Ontario--(Newsfile Corp. - June 13, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for heart disease, announces results from its Annual General Meeting ("AGM") of shareholders held in Toronto, Ontario, on June 12, 2019. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions...
2019-06-13 4:39 PM EDT
Cardiol Therapeutics to Webcast Annual General Meeting on June 12
Oakville, Ontario--(Newsfile Corp. - June 10, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it will be webcasting the informal portion of its annual general meeting (AGM) being held at Vantage Venues, 150 King Street West, 27th Floor, Toronto, on June 12, 2019, at 9:00 a.m. EDT. Following the...
2019-06-10 11:03 AM EDT
Cardiol Therapeutics' Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD
Oakville, Ontario--(Newsfile Corp. - June 3, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for inflammatory diseases, announces that Noramco, Inc. (Noramco) of Wilmington, Delaware, Cardiol's pharmaceutical partner and manufacturer of its pure pharmaceutical CBD, was selected to present at the Food and Drug Administration's (FDA)...
2019-06-03 8:03 AM EDT
Cardiol Therapeutics Commences Trading on the OTCQX
Oakville, Ontario--(Newsfile Corp. - May 30, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it has qualified to trade on the OTCQX® Best Market and begins trading today under the symbol "CRTPF". U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on...
2019-05-30 8:33 AM EDT
Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - March 28, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and development of pharmaceutical cannabidiol and targeted therapies for inflammatory disease, today announced the filing of its audited year-end financial statements and management's discussion and analysis for the year ended December 31, 2018. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website...
2019-03-28 8:47 AM EDT
Cardiol Therapeutics Appoints Thomas Moffatt as Chief Commercial Officer
Oakville, Ontario--(Newsfile Corp. - March 6, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, is pleased to announce the appointment of Thomas (Tom) Moffatt, BBA, as Chief Commercial Officer. Mr. Moffatt was most recently the Chief Operating Officer and Vice-President, Operations at Rx Drug Mart Inc., where he was...
2019-03-06 8:37 AM EST
Cardiol Therapeutics Inc. Closes Over-Allotment
Oakville, Ontario--(Newsfile Corp. - January 18, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announced today that the underwriters for the Company's initial public offering (the "Offering") have exercised their over-allotment option (the "Over-Allotment Option") to purchase an additional 374,544 Class A common shares of...
2019-01-18 9:14 AM EST
Cardiol Therapeutics Completes Initial Public Offering and the Company's Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols "CRDL" and "CRDL.WT"
Oakville, Ontario--(Newsfile Corp. - December 20, 2018) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announces that it has completed its initial public offering (the "IPO") on the Toronto Stock Exchange (the "TSX"). In connection with the IPO, Cardiol issued (a) 3,000,000 units (the "Units") at a price of $5.00 per Unit, with...
2018-12-20 9:27 AM EST
Cardiol Therapeutics Announces Filing of Preliminary Prospectus
Oakville, Ontario--(Newsfile Corp. - September 17, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a biotechnology company specializing in the research and commercial development of novel drug therapies utilizing proprietary drug-delivery systems, is pleased to announce that it has filed a preliminary prospectus with the securities regulatory authorities in each of the provinces of Canada, except Quebec, in connection with a proposed initial public offering (the "Offering") of...
2018-09-17 4:03 PM EDT
Cardiol Therapeutics Appoints Mr. Chris Waddick as Chief Financial Officer, Ms. Anne Tomalin as Director of Regulatory Affairs, and Ms. Dolly Kao as Intellectual Property Counsel
Oakville, Ontario--(Newsfile Corp. - August 30, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company") is pleased to announce the appointment of Mr. Chris Waddick, MBA, CPA, as Chief Financial Officer, Ms. Anne Tomalin, BA, BSc, RAC, as Director of Regulatory Affairs, and Ms. Dolly Kao, BSc, JD, as Intellectual Patent Counsel. Mr. Chris Waddick, MBA, CPA, has thirty years of experience in financial and executive roles in the biotechnology and energy industries, with substantial...
2018-08-30 10:21 AM EDT
Cardiol Therapeutics Appoints Dr. Eldon Smith as Chairman and Ms. Deborah Brown, Mr. Iain Chalmers, and Dr. Guillermo Torre-Amione to its Board of Directors
Oakville, Ontario--(Newsfile Corp. - August 21, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart, is pleased to announce the appointment of Dr. Eldon Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC, as Chairman, and Ms. Deborah Brown, MBA, Mr. Iain Chalmers, MBA, and Dr. Guillermo...
2018-08-21 10:13 AM EDT
Cardiol Therapeutics Closes CDN$10.5 Million Private Placement
Toronto, Ontario--(Newsfile Corp. - May 24, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart, is pleased to announce the successful closing of a brokered private placement (the "Private Placement") of approximately CDN$10.5 million principal amount of unsecured convertible...
2018-05-24 8:36 AM EDT
Cardiol Therapeutics Appoints Dr. James Young as Chair of the Company's Scientific Advisory Board
Toronto, Ontario--(Newsfile Corp. - May 8, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that it has appointed Dr. James Young as Chair of the Company's Scientific Advisory Board. Dr. Young is Professor of Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Chief...
2018-05-08 1:49 PM EDT
Cardiol Therapeutics to Present at the 2018 BIO CEO & Investor Conference in NYC
Toronto, Ontario--(Newsfile Corp. - February 6, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that it will be presenting at the 2018 BIO CEO & Investor Conference, to be held February 12th and 13th, in New York City. Cardiol's President and CEO, David Elsley, will present a corporate overview on Tuesday,...
2018-02-06 10:07 AM EST
Cardiol Therapeutics Demonstrates Novel Way to Target Drugs for Treating Heart Failure Using Nanotechnology
Toronto, Ontario--(Newsfile Corp. - January 9, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that experimental research performed at the Houston Methodist DeBakey Heart & Vascular Center, Texas, shows new functionality of the Company's patented nanotherapeutics. Designed to act as a vehicle to target...
2018-01-09 7:03 AM EST
Cardiol Therapeutics to Present at the 2018 Biotech Showcase in San Francisco
Oakville, Ontario--(Newsfile Corp. - January 3, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that it will be presenting at the 2018 Biotech Showcase in San Francisco. Cardiol's President and CEO, David Elsley, will present a corporate overview on Tuesday, January 9th, 2018 at 2 PM PST at the Hilton San...
2018-01-03 8:03 AM EST